'ADVANCE' (A Pilot Trial)

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

March 21, 2019

Primary Completion Date

November 10, 2020

Study Completion Date

June 30, 2026

Conditions
Breast Cancer
Interventions
DRUG

Paclitaxel

The drug work by damaging the RNA or DNA that tells the cell how to copy itself in division. If the cells are unable to divide, they die.

DRUG

Cyclophosphamide

The drug work by damaging the RNA or DNA that tells the cell how to copy itself in division. If the cells are unable to divide, they die.

DRUG

Carboplatin

The drug work by damaging the RNA or DNA that tells the cell how to copy itself in division. If the cells are unable to divide, they die.

Trial Locations (5)

27103

Novant Health Oncology Specialists, Winston-Salem

91010

City of Hope National Medical Center, Duarte

02115

Dana Farber Cancer Institute, Boston

01757

Dana-Farber/Brigham and Women's Cancer Center (DF/BWCC) at Milford Regional Medical Center, Milford

02190

Dana-Farber/Brigham and Women's Cancer Center (DF/BWCC) in Clinical Affiliation with South Shore Hospital, South Weymouth

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Mayo Clinic

OTHER

lead

Dana-Farber Cancer Institute

OTHER